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PART I: Dose Finding in healthy subjects (n=10)
• Intradermal injection of 3 different doses of maxadilan and placebo on one arm
• Dose escalation over 3 periods with at least 14 days wash-out between periods 
Prestudy: screening

Conclusions
13
ID maxadilan is safe and well tolerated in healthy male subjects.
The dose of 0.9 ng was selected as the most appropriate dose for PART II based on the robust increase in DBF DBF response to 0.9 ng maxadilan is reproducible between arms and between periods A sample size of 10-15 subjects is needed to detect a 30-50% shift between 2 independent groups.
This biomarker can be used to evaluate target-engagement of PAC1 antagonists
